NO-independent regulatory site on soluble guanylate cyclase. - Test2 - elhamkhani - TriplyDB

NO-independent regulatory site on soluble guanylate cyclase.

NO-independent regulatory site on soluble guanylate cyclase.

http://www.wikidata.org/entity/Q32165040

about

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272 Ancient conserved domains shared by animal soluble guanylyl cyclases and bacterial signaling proteins Platelet-derived NO slows thrombus growth on a collagen type III surface Comparison of the properties of the five soluble guanylyl cyclase subunits in Drosophila melanogaster.Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction?Breakthrough in heart failure with preserved ejection fraction: are we there yet?Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction Drug treatment of pulmonary hypertension in children PAS-mediated Dimerization of Soluble Guanylyl Cyclase Revealed by Signal Transduction Histidine Kinase Domain Crystal Structure Heme-dependent and independent soluble guanylate cyclase activators and vasodilation.Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs The Concise Guide to PHARMACOLOGY 2013/14: enzymes.Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study Protective effects of YC-1 against glutamate induced PC12 cell apoptosis.Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.Incorporation of tyrosine and glutamine residues into the soluble guanylate cyclase heme distal pocket alters NO and O2 binding.Nitric oxide/cGMP pathway signaling actively down-regulates α4β1-integrin affinity: an unexpected mechanism for inducing cell de-adhesion.YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components Drugs of abuse and stress impair LTP at inhibitory synapses in the ventral tegmental area.Future prospects in the treatment of erectile dysfunction: focus on avanafil.Targeting soluble guanylate cyclase for the treatment of pulmonary hypertension.Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.Heme oxygenase-1 deficiency leads to alteration of soluble guanylate cyclase redox regulation.The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction.Cellular targets of nitric oxide in the hippocampus.Nitric oxide donor drugs: current status and future trends.The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function.A Rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies

P2860

Q24656131-34B357BA-5AEC-48DC-95F0-2C737130A934 Q24798007-3BF74EED-31E4-4C9D-A17B-E33A8AA4C550 Q24798253-03F7F459-FD87-4513-8492-FE4EEEEB79A5 Q24800867-C1947878-C8FE-4D67-A4BE-61E78F65023C Q24815038-4B2B2CA3-A9D5-44FC-9BDB-4D99BB9A4515 Q26765931-BD6F8CB5-9516-4074-A962-33E28719312E Q26771999-E8F68D74-A488-4426-B6EA-A88D6304D5C2 Q26853363-21606AEA-E3AC-406C-B3D2-FD72DEAC8E2B Q26996078-26343BBC-4863-4D9A-8735-319AABE682D6 Q27649070-8BA896B9-EB34-4C23-84E7-0EA3CB2AF12F Q27692662-1E782943-5F5C-4B63-9943-E8BC87275D2C Q28482185-06A12329-8579-4ABF-9E19-735928D96D2A Q28513504-87B67E1A-5681-4C9A-B0B1-DE91E1F60F64 Q28580525-C7841380-9D55-45B9-B0B6-DB34DFCFA801 Q30486745-D1F4D2BD-7AFA-4173-B2F2-231986001F63 Q30503997-7175F3DA-F009-4762-9C7B-07F5F444F4CA Q33209298-F5CC7385-BB17-4101-BFB7-2A9FF67671B2 Q33589713-BD26DC19-1D33-495A-A1DA-19766CA6AF8D Q33743118-CEE4B6A8-1153-4FAB-A2C5-EA69221009F7 Q33772904-C8DB65D0-0081-45C1-AFCD-1DAC439FBB07 Q33885131-0B247384-149A-4DF0-B334-DF43FD8C78AE Q33903491-C2F4121B-05FA-46FA-9F1E-207598010312 Q33948966-E2CAD30B-4E12-447C-A628-9E5D53C90240 Q34013689-626619D9-BB84-4BAF-A84B-E8BF6F24A341 Q34029414-EB08A9F8-9281-43EA-ABDF-349D0AB03016 Q34179857-517466CC-8B73-4DA2-A619-E286E1FA723D Q34212268-9EECCEC1-1F3B-4D7B-B98C-154929D00CF6 Q34214656-954508AC-0C06-4AE0-9BBF-DDCE47862DF1 Q34389020-0ADFB180-0DDD-45EE-B5C0-86059A378DA0 Q34469717-F69F7D26-283A-48CD-BC79-15D8293A2B93 Q34564998-33D76C88-2E9E-496F-9BEE-D1E1341377D1 Q34603335-D8698230-1D83-4F4D-B136-920E4307F58F Q34628644-0A8108B3-0144-4F43-AB27-A15BAD5E4D63 Q34981386-90951A8D-A153-41D2-A95F-19E40586D386 Q34981737-A2DD080B-5E8E-4647-B186-E476A8E30EF3 Q34983511-52424A07-A439-4020-BED3-180D4DB90731 Q35001011-7A58FD02-73F3-4854-B2D2-47A01C6BA5C8 Q35010064-F2173299-67C4-405F-803B-030AF12824E8 Q35044037-E9EE5245-5646-4581-ACF8-B82698CD9E58 Q35044042-27128FBA-260A-4A5F-BFA0-CE3BFC374A5C

P2860

NO-independent regulatory site on soluble guanylate cyclase.

http://www.wikidata.org/entity/Q32165040

description

2001 nî lūn-bûn

@nan

2001 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մարտին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

NO-independent regulatory site on soluble guanylate cyclase.

@ast

NO-independent regulatory site on soluble guanylate cyclase.

@en

type

label

NO-independent regulatory site on soluble guanylate cyclase.

@ast

NO-independent regulatory site on soluble guanylate cyclase.

@en

prefLabel

NO-independent regulatory site on soluble guanylate cyclase.

@ast

NO-independent regulatory site on soluble guanylate cyclase.

@en

P1433

Q32165040-E08041EC-3B73-452C-A494-52D58F61663F

P1476

Q32165040-151C8ACE-9023-40F7-B1D5-E3AB5A86B979

P2093

Q32165040-07299601-7607-4AFF-A942-EDBE633281B8

Q32165040-2C0730BE-98ED-48CB-A21B-2E3DE25D7E12

Q32165040-3294CB73-A18B-4B2C-BDB7-F1D66558A7F8

Q32165040-33DCD3CF-A57E-48D7-BC08-2BEE9C66418D

Q32165040-4419039F-57F0-4A8A-B4BA-AA0ADF17946E

Q32165040-4DE3C699-3ECA-408F-9663-B4888F584E1A

Q32165040-51AD5672-8573-45EE-BC01-7B781C127A01

Q32165040-6D9196DA-BA4E-4E78-B18E-90FB1E1C66C4

Q32165040-97B94DE4-4E7C-44C3-B25E-F03F80155E8D

Q32165040-A149C58B-EC89-4D50-91B9-04971D611909

P2860

Q32165040-44BF20F8-2950-4476-8C36-8AC65DE66A83

Q32165040-4EAAD795-04EB-499E-A809-A82A34E5D851

Q32165040-5D5517F1-F756-4DF1-8724-6AD3E83D53E4

Q32165040-63BA3DF4-1C60-475B-A5A3-F261FE5CC821

Q32165040-98D2E1FB-BE18-484B-9555-EDFB0B1940B8

Q32165040-A2BA9F10-507B-4B6E-ADCE-88B4E68D76D3

Q32165040-B2028088-A06D-4FCF-9990-48F881CB8D62

Q32165040-BEC6F880-8DF4-4CCE-B22D-12FFD36FCAEA

Q32165040-EDACDCCD-453C-418E-94C2-C94FF57C365A

P2888

Q32165040-4D6750CD-1CB3-4E31-B8DA-DE6CC357C881

P304

Q32165040-D6729593-9AD4-45F1-AC17-8743C03226A2

P31

Q32165040-79DA70D4-49E7-431D-804F-0C0DC653E000

P356

Q32165040-479434EB-6E60-4530-B64F-620B7DA19FE4

P407

Q32165040-F6769ADB-8D45-48F7-B92C-CAA25D92971A

P433

Q32165040-8E6750E6-78BF-4110-BF42-0256F7131058

P478

Q32165040-CB843442-1C12-43B1-83B4-FB8068A79D69

P577

Q32165040-ADA2620B-C64B-41B0-835A-047064A48FEF

P6179

Q32165040-77BBF1F4-62EF-4076-B91E-C58505FACF2E

P698

Q32165040-811DE417-549D-4BD6-BC77-145DD2D2EB9E

P921

Q32165040-D3930E91-9790-4BE8-B270-BC9F7D17BEFC

P356

P1433

P1476

NO-independent regulatory site on soluble guanylate cyclase.

@en

P2093

Alonso-Alija C

http://www.w3.org/2001/XMLSchema#string

Apeler H

http://www.w3.org/2001/XMLSchema#string

Becker EM

http://www.w3.org/2001/XMLSchema#string

Dembowsky K

http://www.w3.org/2001/XMLSchema#string

Feurer A

http://www.w3.org/2001/XMLSchema#string

Gerzer R

http://www.w3.org/2001/XMLSchema#string

Minuth T

http://www.w3.org/2001/XMLSchema#string

Perzborn E

http://www.w3.org/2001/XMLSchema#string

Pleiss U

http://www.w3.org/2001/XMLSchema#string

Schramm M

http://www.w3.org/2001/XMLSchema#string

P2860

Human soluble guanylate cyclase: functional expression and revised isoenzyme family

Cleavage of structural proteins during the assembly of the head of bacteriophage T4

YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase

Generation and characterization of a stable soluble guanylate cyclase-overexpressing CHO cell line.

Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide.

Kinetics and equilibria of soluble guanylate cyclase ligation by CO: effect of YC-1.

Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity.

Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.

Different effects of ANP and nitroprusside on cyclic GMP extrusion of isolated aorta.

P2888

P304

212-215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/35065611

http://www.w3.org/2001/XMLSchema#string

P407

P433

6825

http://www.w3.org/2001/XMLSchema#string

P478

410

http://www.w3.org/2001/XMLSchema#string

P577

2001-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049910466

http://www.w3.org/2001/XMLSchema#string

P698

11242081

http://www.w3.org/2001/XMLSchema#string

P921